Gram Research analysis shows that combining an experimental RNA therapy targeting ZFP423 with semaglutide (a GLP-1 weight loss drug) produced greater fat loss while preserving lean muscle mass in mice, compared to either treatment alone. The combination also improved blood sugar control, insulin sensitivity, and liver health. However, this research is preliminary and conducted only in animals; human clinical trials would be needed before this approach could be used in people.

Scientists discovered a new way to improve weight loss medications like Ozempic and Wegovy. When they combined these popular GLP-1 drugs with an experimental RNA therapy that boosts fat-burning in the body, mice lost more fat while keeping their muscle mass intact. The combination also improved blood sugar control and liver health better than either treatment alone. This research, published in a top science journal, suggests a future approach to making weight loss healthier and more sustainable by targeting how the body burns energy.

Key Statistics

A 2026 research article published in the Proceedings of the National Academy of Sciences found that combining an RNA therapy targeting ZFP423 with the GLP-1 drug semaglutide produced greater weight and fat loss in mice while preserving lean muscle mass compared to either treatment alone.

According to research reviewed by Gram, the combination therapy in mice improved glucose homeostasis, insulin sensitivity, lipid metabolism, and reduced hepatic steatosis (fatty liver disease) more effectively than monotherapy with either treatment.

The experimental RNA therapy successfully converted white fat cells into beige fat cells that burn energy and produce heat, increasing body temperature and oxygen consumption in treated mice.

The Quick Take

  • What they studied: Whether combining a new RNA therapy with GLP-1 weight loss drugs could help people lose fat while keeping muscle and improving overall metabolic health.
  • Who participated: Laboratory mice, including both lean mice and mice made obese through high-fat diets, to test the safety and effectiveness of the combination treatment.
  • Key finding: When researchers combined the experimental RNA therapy (targeting a protein called ZFP423) with semaglutide (a GLP-1 drug), mice lost significantly more fat than with either treatment alone while preserving lean muscle mass and showing better blood sugar control.
  • What it means for you: This research is still in early stages using animal models, but it suggests a future possibility for improving weight loss medications to preserve muscle and metabolic health. However, human clinical trials would be needed before any application to people.

The Research Details

Researchers conducted laboratory experiments in mice to test a new RNA therapy approach. They used antisense oligonucleotides, which are short pieces of genetic material designed to turn off a specific protein called ZFP423. This protein normally prevents fat cells from becoming brown fat, which burns energy and produces heat. The scientists tested this RNA therapy alone and combined it with semaglutide, a GLP-1 receptor agonist (the active ingredient in weight loss drugs like Ozempic). They measured changes in body weight, fat loss, muscle preservation, body temperature, oxygen consumption, blood sugar control, and liver health. The study included both normal-weight mice and mice that had been made obese through high-fat diets to test effectiveness across different starting conditions.

Current weight loss medications like GLP-1 drugs work primarily by reducing appetite, but they often cause people to lose muscle along with fat and can slow down metabolism. This can make weight regain more likely after stopping treatment. By combining appetite suppression with a therapy that increases energy expenditure through fat-burning, researchers aimed to create a more complete solution that preserves muscle and maintains metabolic health. This approach targets the root problem from two angles simultaneously.

This research was published in the Proceedings of the National Academy of Sciences, one of the most prestigious scientific journals in the world. The study used controlled laboratory conditions with mice, allowing researchers to carefully measure multiple health markers. However, results in mice do not automatically translate to humans, and the sample size for animal studies was not specified in the abstract. Human clinical trials would be necessary to confirm safety and effectiveness in people.

What the Results Show

The RNA therapy targeting ZFP423 successfully converted white fat cells into beige fat cells, which burn energy and produce heat. Treated mice showed increased body temperature and oxygen consumption, indicating higher metabolic activity. When combined with semaglutide, the therapy produced greater weight loss and fat loss compared to either treatment alone. Importantly, the combination preserved lean muscle mass, whereas GLP-1 drugs alone often cause muscle loss during weight reduction. The combination also improved glucose homeostasis (blood sugar control) and insulin sensitivity, meaning the body’s cells responded better to insulin and maintained healthier blood sugar levels. Additionally, the treatment improved lipid metabolism (how the body processes fats) and reduced hepatic steatosis (fatty liver disease), a common complication of obesity.

The RNA therapy improved mitochondrial respiration, which means the energy-producing structures inside cells worked more efficiently. This enhanced cellular energy production supports the overall metabolic improvements observed. The therapy also showed benefits in lean mice without obesity, suggesting potential applications beyond weight loss treatment. The combination approach appeared to address multiple aspects of metabolic dysfunction simultaneously rather than targeting just appetite or just energy expenditure.

Previous research has shown that GLP-1 drugs effectively reduce weight and improve blood sugar control, but they often result in loss of lean muscle mass and reduced energy expenditure, which can lead to metabolic slowdown and weight regain. This study builds on earlier discoveries about brown and beige fat’s role in metabolism and adds a new dimension by combining appetite suppression with thermogenesis activation. The finding that ZFP423 controls the pathway for diet-induced thermogenesis represents a novel mechanistic insight that hadn’t been previously exploited therapeutically.

This research was conducted entirely in mice, which have different physiology and metabolism than humans. Results in animal models frequently do not translate directly to human outcomes. The study did not include human participants, so safety, tolerability, and effectiveness in people remain unknown. The sample sizes for the animal studies were not specified in the available abstract. Long-term effects of the RNA therapy were not evaluated. The study did not examine what happens after treatment stops or whether the benefits persist over extended periods.

The Bottom Line

This research is preliminary and should not influence current treatment decisions. People currently using GLP-1 medications should continue following their doctor’s guidance. For those interested in weight loss, current evidence supports GLP-1 drugs as effective treatments, though combining them with resistance exercise may help preserve muscle mass. This RNA therapy approach shows promise but requires human clinical trials before any recommendation can be made. Confidence level: Low for human application at this stage.

This research is most relevant to people with obesity who are considering or using GLP-1 medications and are concerned about muscle loss. It may also interest people with metabolic disorders like type 2 diabetes. Healthcare providers and pharmaceutical researchers should monitor this development. People currently on weight loss medications should not change their treatment based on this preliminary research. Those with liver disease or metabolic disorders should discuss any future treatments with their doctors.

This research is in early laboratory stages. If human trials begin soon, it would typically take 5 to 10 years before any new therapy could become available to patients. Even then, it would need to pass safety and effectiveness testing in multiple phases of clinical trials. People should not expect this treatment to be available in the near future.

Frequently Asked Questions

Can I use this new RNA therapy to preserve muscle while taking GLP-1 weight loss drugs?

This therapy is not yet available for human use. The research was conducted only in mice and has not entered human clinical trials. Current evidence-based ways to preserve muscle during GLP-1 treatment include resistance training 2 to 3 times weekly and adequate protein intake.

How does this RNA therapy work differently from GLP-1 medications?

GLP-1 drugs reduce appetite to lower calorie intake. This RNA therapy increases energy expenditure by converting fat cells into brown fat that burns calories for heat. The study suggests combining both approaches targets weight loss from two different angles simultaneously.

When will this treatment be available for people with obesity?

This research is in early laboratory stages. If human trials begin immediately, it would typically take 5 to 10 years for regulatory approval and availability. Currently, no timeline for human testing has been announced.

Does this research mean GLP-1 drugs are bad for muscle loss?

GLP-1 drugs are effective for weight loss and metabolic health, but they can cause some muscle loss during treatment. This research suggests combining them with therapies that boost energy expenditure could reduce muscle loss, but current strategies like resistance training also help preserve muscle.

What is ZFP423 and why does blocking it help with weight loss?

ZFP423 is a protein that normally prevents fat cells from becoming brown fat, which burns energy and produces heat. By blocking ZFP423, the therapy converts regular fat cells into energy-burning brown fat, increasing overall metabolic rate and fat loss.

Want to Apply This Research?

  • Users could track body composition changes (muscle versus fat) using bioelectrical impedance scales or DEXA scans every 4 to 8 weeks, rather than relying solely on total weight, to monitor whether their weight loss includes muscle preservation.
  • Users on GLP-1 medications could use the app to log resistance training sessions (strength exercises) 2 to 3 times weekly, which research shows helps preserve muscle during weight loss, complementing the goals this study identified.
  • Implement a dashboard tracking three metrics: total weight, estimated muscle mass, and fat mass percentage. Set monthly goals for preserving or gaining muscle while losing fat, creating awareness of body composition changes beyond the scale.

This research is preliminary and conducted only in laboratory mice. It has not been tested in humans and no human clinical trials have been announced. These findings should not influence current medical treatment decisions. People taking GLP-1 medications should continue following their healthcare provider’s guidance. This article is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making changes to weight loss or metabolic health treatment plans. Future human studies may yield different results than those observed in animal models.

This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.

Source: An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss. , Proceedings of the National Academy of Sciences of the United States of America (2026). PubMed 42789307 | DOI
Topics
GLP-1 weight loss drugs muscle preservation during weight loss RNA therapy obesity brown fat thermogenesis metabolic health semaglutide combination therapy lean mass preservation fat loss treatment